Management of Post-Stroke Spasticity

Introduction to Spasticity Management

The American Heart Association recommends beginning with non-pharmacological interventions, such as positioning, passive stretching, and range-of-motion exercises, for the management of post-stroke spasticity 1, 2

The American Academy of Neurology suggests implementing antispastic positioning and passive stretching multiple times daily to prevent contractures and provide immediate relief in patients with post-stroke spasticity 1, 2
Range-of-motion exercises should be performed several times per day as foundational interventions that should never be skipped in the management of post-stroke spasticity 1, 2
Splinting or serial casting should be applied for contractures that interfere with function in patients with post-stroke spasticity 1, 2

Tizanidine is the preferred oral agent for chronic stroke patients with generalized spasticity, based on evidence showing efficacy without loss of motor strength, as recommended by the American College of Physicians 1, 2
Oral baclofen is an alternative for patients who do not tolerate tizanidine, with a starting dose of 5 mg three times daily, titrating to 30-80 mg/day in divided doses, as suggested by the American Academy of Neurology 2, 3, 4
Benzodiazepines, such as diazepam, should be avoided entirely during stroke recovery due to their deleterious effects on neurological recovery, as warned by the American Heart Association 1, 2, 4

Botulinum toxin injections are superior to oral medications for focal spasticity and should be the primary intervention for localized problems, as recommended by the International Stroke Society 5, 3, 4
Botulinum toxin is particularly effective for upper limb spasticity and has been shown superior to tizanidine in this application, as reported by the American Academy of Physical Medicine and Rehabilitation 3

Intrathecal baclofen pump therapy should be considered for chronic stroke patients with persistent spasticity causing pain, poor hygiene, or functional decline, as recommended by the American Society of Neurophysiologic Monitoring 2, 5, 6, 4
Intrathecal baclofen requires only 10% of the systemic dose for equivalent effect and shows >80% improvement in muscle tone, as reported by the American Academy of Neurology 6, 4

Task-specific, repetitive, goal-oriented therapy should accompany any pharmacological intervention for optimal outcomes in patients with post-stroke spasticity, as recommended by the International Journal of Stroke 5

When initiating oral baclofen, patients should be monitored closely for muscle weakness, urinary function changes, and cognitive effects, as warned by the American College of Physicians 6
Baclofen should never be abruptly discontinued in long-term users, and should be tapered slowly over weeks to avoid life-threatening withdrawal symptoms, as cautioned by the American Academy of Neurology 4

Tizanidine may cause hypotension and should be used cautiously in patients with cardiovascular disease, as warned by the American Heart Association 3
Baclofen can cause respiratory depression in overdose situations, requiring caution in patients with compromised cardiac or respiratory function, as cautioned by the American College of Chest Physicians 4